This $352,141 Project Grant from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) program will support research at Wayne State University to address racial disparities in HER2+ breast cancer outcomes. The project aims to (1) characterize race-specific immune profiles and genetic factors that contribute to differential response to anti-HER2 antibody therapies, and (2) strengthen infrastructure to facilitate translational research on immuno-oncology and cancer health disparities. This work will inform more equitable, race-inclusive precision medicine approaches to improve overall treatment response and reduce racial disparities in immuno-oncology outcomes. The award period runs from Sep 2024 to Aug 2026 and represents part of NCI's broader investment in advancing cutting-edge cancer research and reducing health disparities.
Generated 3/4/25, 5:30 AM